3,4 In parallel, renal failure also predisposes to poorer glycaemic control (both hyper- and hypoglycaemia) because of an altered renal physiology, which disrupts normal glucose and insulin metabolism
Arch Pharm Res 37(1):13 Lemoine AJ, Revollo S, Villalpando G, Valverde I, Gonzales M, Laouafa S, Soliz J, Joseph V (2018) Divergent mitochondrial antioxidant activities and lung alveolar architecture in the lungs of rats and mice at high altitude
Retatrutide Structure and Chemistry Retatrutide builds on the engineering principles refined in semaglutide and tirzepatide: Glucagon-based peptide backbone retatrutide is derived from glucagon, with modifications to give it activity at all three target receptors Strategic amino acid substitutions multiple substitutions tune the receptor activity balance across GLP-1R, GIPR, and glucagon receptor Fatty acid chain attached for albumin binding and extended half-life (similar strategy to semaglutide and tirzepatide) Aminoisobutyric acid substitutions protect against DPP-4 enzymatic degradation The triple-agonist design is technically demanding because each receptor has different binding requirements
to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and adults with overweight in the presence of at least one weight-related comorbid condition Limitations of Use: Concomitant use of Wegovy injection with other semaglutide-containing products or with any GLP-1 receptor agonist is not recommended Important Safety Information for Wegovy WARNING: RISK OF THYROID C-CELL TUMORS In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures
Our clinic team responds within minutes on WhatsApp
